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Abstract objectives To investigate antiretroviral therapy (ART) uptake after its introduction in 2004 in a
longitudinal population-based cohort and its nested clinical cohort in rural Uganda.
methods A HIV serosurvey of all adults aged ‡15 years is conducted annually. Two intervals were
selected for analysis. Interval 1 (November 2004–October 2006) provided 2 years of follow-up to
prospectively evaluate access to HIV services. Interval 2 (November 2007–October 2008) was used to
evaluate current coverage of services. Logistic regression was used to identify sociodemographic factors
associated with ART screening within 2 years of diagnosis. ART coverage was assessed using Weibull
survival models to estimate the numbers needing ART.
results In Interval 1, 636 HIV-positive adults were resident and 295 (46.4%) knew their status. Of
those, 248 (84.1%) were screened for ART within 2 years of diagnosis. After adjusting for age, those
who were widowed, separated or never married were more likely to be screened than those who were
married. In Interval 2, 575 HIV-positive adults were residents, 322 (56.0%) knew their status, 255
(44.3%) had been screened for ART and 189 (32.9%) had started ART. Estimated ART coverage was 66%.
conclusions In this cohort, ART access and uptake is very high once people are diagnosed. Owing to
intensive screening in the study clinic, nearly all participants who were eligible initiated ART. However,
this is unlikely to reflect coverage in the general population, intensified efforts are needed to promote
HIV testing, and ART screening and uptake are needed among those found to be HIV-positive.
keywords antiretroviral therapy, Uganda, access and uptake, cohort study
Introduction
Antiretroviral therapy (ART) has led to the improved
health of many HIV-infected people and is a cost-effective
intervention, as it makes HIV infection a chronic man-
ageable disease, allowing HIV-infected people to live well
and to be socially and economically active (Badri et al.
2006). While globally, the number of adults and children
living with HIV increased from 29 million in 2001 to
33.4 million in 2008, the number of HIV-related deaths
rose only from 1.9 million to 2 million over the same
period, largely due to ART scale-up (UNAIDS ⁄WHO,
2009).
There are many challenges in meeting the demand for
ART in sub-Saharan Africa (Loewenson & McCoy 2004),
the region most badly affected by HIV, with 70% of the
world’s HIV-related deaths (UNAIDS ⁄WHO, 2009). At
the end of 2008, an estimated 44% of adults and children
(nearly 3 million people) in need of ART in sub-Saharan
Africa were receiving it (UNAIDS ⁄WHO 2009). Barriers to
ART access and uptake in Africa include misperceptions,
distance to the ART providers and fear of side-effects of
divorce or rejection by spouses, of stigma following HIV
serostatus disclosure to friends and relatives, and of taking
medicines for life (Murray et al. 2009).
Information on ART access and uptake is important in
planning comprehensive HIV care services. Overcoming
particular barriers to ART access among hard-to-reach
populations, including those in rural areas (Zachariah
et al. 2006), is critical if countries are to achieve universal
access to ART. A longstanding population-based cohort in
rural Uganda and its nested clinical cohort provided the
opportunity to assess ART access and uptake and to
investigate possible associated demographic factors.
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Methods
Study setting
Adult HIV prevalence in Uganda fell from a peak of
around 15% in 1991 to 5% in 2001 (Uganda STD ⁄AIDS
Control programme 2002) with recent signs of a possible
resurgence (Uganda AIDS Commission 2007). An open
general population cohort in rural southwest Uganda was
established in 1989 for HIV surveillance, and now com-
prises approximately 20,000 residents of 25 neighbouring
villages about 30 km from Lake Victoria. There are no
tarmac roads, and access may be difficult during the rains.
The population is ethnically homogeneous with most
people belonging to the Baganda tribe and 15% being of
Rwandese origin (Nakibinge et al. 2009). Half the popu-
lation is under 15 years of age. HIV prevalence in the study
area declined from 8.5% in 1990 to 6.2% in 1999 ⁄2000,
but thereafter rose to 7.7% in 2004 ⁄2005 (Shafer et al.
2008).
Population cohort and annual HIV serosurvey
Full details of the population cohort and annual HIV
serosurvey have been published elsewhere (Mulder et al.
1994; Mbulaiteye et al. 2002). In brief, household surveys
of consenting participants aged at least 13 years have been
conducted annually since 1989, with all study village
residents eligible for inclusion. Consenting residents are
interviewed at home in the local language by trained survey
staff and provide a blood sample for HIV testing. Survey
rounds begin in November and end in October the
following year. Participants are also encouraged to attend
one of the five free voluntary counselling and testing (VCT)
centres provided by the research programme in the study
villages and at the study clinic. During the survey,
participants are asked if they would like to receive their
HIV test results, and if they have ever received their results
in the past. Participants who indicate that they would like
to receive their test result are referred to the VCT centres,
where they are informed of their result and counselled.
Diagnosis of HIV infection (i.e. having a test and learning
the result) is the first step in access to ART.
Clinical cohort
The clinical cohort has been described in detail elsewhere
(Morgan et al. 1997). In brief, in 1990, a random selection
of one-third of the HIV-positive adults identified in the first
population cohort HIV serosurvey were invited to join a
clinical cohort as prevalent cases. In addition, all adult HIV
seroconverters identified during subsequent annual sero-
surveys were invited to enrol in the clinical cohort as HIV
incident cases. HIV-negative controls randomly selected
from the population cohort to match the age and gender of
the HIV prevalent and incident cases, were also invited to
enrol. Study clinicians were initially blinded to the partic-
ipants’ HIV serostatus and were un-blinded in 2004 when
ART was introduced. As participants who consent to the
annual HIV serosurvey may opt not to know their HIV
serostatus, some of those invited to enrol are unaware of
their HIV serostatus and are therefore encouraged to access
VCT at the centres in the study area and at the study clinic.
Consenting individuals are enrolled in the clinical cohort
and attend medical follow-up visits at the study clinic every
3 months. In January 2004, HIV care in the clinical cohort
was extended to include ART provision for eligible and
consenting participants.
Other HIV-positive individuals from the population
cohort who present at the study clinic with symptoms and
signs of HIV infection and those identified through the
VCT centres are offered ART care, if eligible. These
individuals are also invited to enrol in the clinical cohort.
The study clinic is the only ART provider in the area
(ART is not provided at the local government health
centre or at the VCT centres). It is likely that very few
individuals from the study population who are eligible for
ART obtain it from other providers, as these are outside
of the area (the nearest about 10 km away), and reaching
them requires substantial efforts in time and transport
costs.
ART initiation
HIV-positive participants in the clinical cohort who know
their HIV status undergo regular 3 monthly follow-up,
including screening for ART eligibility according to
national guidelines: CD4 count £200 cells ⁄mm3 regardless
of WHO clinical stage, WHO clinical stage 4 irrespective
of CD4 count; persistent or recurrent WHO clinical stage 3
disease irrespective of CD4 count; and pregnant women
with CD4 count £250 cells ⁄mm3 (Uganda Ministry of
Health 2003).
Intensive preparations for HIV-positive patients eligible
for ART include three counselling visits, a medical exam-
ination and identification of a treatment adherence sup-
porter. On starting ART, patients are seen at the clinic after
2 weeks, 4 weeks and then at 3-monthly intervals, or more
often in case of interim illnesses or drug side-effects. First
line treatment consists of a combination of zidovudine
(AZT), lamivudine (3TC) and nevirapine (NVP), with the
possibility of switching to stavudine (d4T) in case of AZT
toxicity, and to efavirenz (EFZ) in case of NVP toxicity or
concurrent tuberculosis treatment. Participants who are
not yet eligible for ART start cotrimoxazole prophylaxis
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and receive an appointment for re-screening for ART
eligibility.
Laboratory methods
HIV serostatus was determined by two independent
enzyme immunoassays (EIA) 5 (College of American
Pathologists, 325 Waukegan Road, Northfield Illinois
60093-2750 USA) using a parallel set algorithm, with
Western blot to resolve discordance between EIA results
(Nunn et al. 1993). CD4 cell counts were measured using
the FACS Count machine (Becton Dickinson, San Jose, CA,
USA).
Statistical methods
Data were analysed using Stata 10 (StataCorp, College
Station, TX, USA). All adult participants (defined as
aged ‡15 years) were included in the analysis if they had
tested HIV-positive at any annual HIV survey, and were
resident in the study area during the selected survey. Two
intervals were selected for analysis: Interval 1 from
November 2004 to October 2006 (i.e. the 2004 ⁄5 and
2005 ⁄6 surveys) and Interval 2 from November 2007 to
October 2008 (i.e. the 2007 ⁄8 survey). As complete data
on HIV services were not available after 2008, Interval 1
was chosen as a period after the early phase of ART
introduction which allowed at least 2 years of follow-up to
prospectively evaluate access to HIV care. Interval 2 was
chosen as the most recent period for which complete
information was available to estimate the current number
who were HIV-infected, and who had accessed care and
treatment.
Records were obtained from all VCT centres in the study
villages of all participants who had received their HIV test
results between January 2004 and the end of 2008. ART
screening records from the clinical cohort were used to
identify those participants who had received their HIV
results from the study clinic, as all persons who receive
their results in the clinic are screened for ART eligibility.
HIV diagnosis was defined as receiving one’s positive test
result (either through a VCT centre or the study clinic).
Individuals who reported receiving their results since
testing HIV-positive in a serosurvey, but for whom there
was no record at the VCT centre, were also considered to
have been diagnosed. The date of diagnosis was defined as
the earliest of the date of recorded VCT, ART screening
or reported receipt of a positive result.
Interval 1 was used to explore factors associated with
ART screening within 2 years of diagnosis. HIV-positive
participants who had been diagnosed (i.e. received their
positive test result) by end 2006 were followed prospec-
tively to assess those who had been screened within 2 years
of their diagnosis. Participants who died or moved away
after their diagnosis were included in the analysis.
Cross-tabulations and chi square tests were conducted to
assess associations between socio-demographic character-
istics and being screened for ART within 2 years of
diagnosis. Logistic regression was used to estimate crude
and adjusted odd ratios (OR) and 95% confidence intervals
(CI) for the associations between socio-demographic
characteristics and ART screening. Age was included as an
a priori confounder. Factors whose age-adjusted associa-
tion with screening reached P < 0.20 were included in a
multivariable model; those that remained associated at
P < 0.10 were retained.
Interval 2 was used in calculating the proportion of HIV-
infected participants still alive who had been diagnosed
since the introduction of ART in 2004, and the proportion
of those diagnosed who had been screened for ART
eligibility. ART uptake was calculated as the proportion of
those diagnosed and found eligible after screening who
initiated ART. HIV-infected participants who had died or
moved away before the 2007 ⁄8 HIV survey were excluded
from the analysis.
Interval 2 was also used in estimating ART coverage
relative to ART need, based on the 2003 Uganda Ministry
of Health treatment guidelines (CD4 count threshold of
200 cells ⁄mm3). Coverage is defined as the number of
individuals receiving ART at a point in time divided by the
number of individuals who are eligible to receive treatment
at the same point in time (including those who are already
receiving ART) (Mahy et al. 2010). A Weibull model was
used to estimate age-specific mortality among all HIV-
positive adults in the population cohort in the absence of
ART. The Weibull regression parameters were used to
construct an age-based model life table to calculate the
conditional probability of survival to the age of ART need
from the age at seroconversion, or from the age at the first
positive HIV test in prevalent cases (Zaba et al. 2012). The
date of seroconversion was calculated as the midpoint
between the last documented negative HIV test and the first
documented positive HIV test. Estimates of the number
of participants needing ART at the end of 2008 were
generated using survival time post-infection with the
assumption that HIV-positive participants need ART
approximately 3 years before otherwise expected death in
the absence of ART (Schneider et al. 2004; Zwahlen 2008).
Ethical approval
The study was part of a programme of research approved
by the Science and Ethics Committee of the Uganda Virus
Research Institute and the Uganda National Council of
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Science and Technology, and all participants gave
informed consent.
Results
During Interval 1 (the 2004 ⁄5 and 2005 ⁄6 surveys), 636
HIV-positive adults were resident in the study area, and by
the end of 2006, 295 (46.4%) had been diagnosed
(received their test results). Most (N = 201, 68.1%) had
first received their positive result at the study clinic – the
other 94 (31.9%) had received their result at a VCT centre
(Table 1). However, 36 of those who reported receiving
their results at a VCT centre had no confirmed record of
diagnosis. The majority of those diagnosed were women
(N = 178, 60.3%), aged between 25 and 44 years at the
time of diagnosis, and had completed primary education or
higher. Among those diagnosed, 248 (84.1%) had been
screened for ART eligibility within 2 years of diagnosis. Of
the 47 who had not been screened within 2 years, 10
(21.3%) had moved out of the study area after their
diagnosis and 7 (14.9%) had died.
Among the 295 HIV-positive participants in Interval 1
who were diagnosed by end 2006, there was some evidence
in the unadjusted analysis that participants who were
married were less likely to be screened for ART within
2 years of diagnosis (Table 2). No other sociodemographic
factors were associated with screening in the unadjusted
analysis. After adjusting for age as an a priori confounder,
there was still some evidence of an association with marital
status. Widowed, separated or never-married participants
were more likely to be screened than married participants
(adjusted OR = 2.72, 95% CI = 0.98–7.58, for widowed
vs. married; adjusted OR = 4.97, 95% CI = 0.57–43.5 for
never married vs. married). There was no evidence of an
independent association between other the socio-demo-
graphic factors and screening for ART. Furthermore, the
unadjusted and adjusted ORs were similar, indicating no
important confounding of sociodemographic factors.
During Interval 2 (the 2007 ⁄8 survey), 575 adults had
tested HIV-positive in any annual HIV survey and were
still alive and resident in the study area. Of those, 322
(56.0%) had been diagnosed (received their test results)
and knew that they were HIV-positive. By the end of 2008,
255 of those diagnosed (79.2%) had been screened for
ART. Among those screened, 191 (74.9%) had ever been
eligible to initiate ART, and of those who were eligible,
189 (99.0%) had initiated ART. The proportion of
participants diagnosed, screened and started ART by
gender and age group are shown in Figures 1a,b.
Among the 575 HIV-positive participants resident in
Interval 2, it was estimated that 274 (48%) were in need of
ART, of whom 189 (69%) had initiated treatment by end
2008 (Table 3). Coverage was slightly lower in males than
females (64% vs. 72%, respectively). Coverage varied with
age, from 55% in those aged 15–24 years to 86% in those
Table 1 Characteristics of 295 HIV-infected adults who were
resident in the study area in Interval 1* and who knew their HIV
status by end 2006
N (%)
Gender
Men 117 (39.7)
Women 178 (60.3)
Age (years) at diagnosis
<25 30 (10.2
25–34 105 (35.6
35–44 106 (35.9)
45+ 54 (18.3
Marital status at diagnosis
Never Married 14 (4.7)
Married 136 (46.1)
Divorced ⁄ separated 77 (26.1)
Widowed 62 (21.0)
Not known 6 (2.0)
Education level at diagnosis
None 34 (11.5)
Primary 1–4 61 (20.7)
Primary 5–7 114 (38.6)
Secondary or higher 54 (18.3)
Unknown 32 (10.8)
Tribe
Baganda 191 (64.7)
Non-Baganda 95 (32.2)
Unknown 9 (3.1)
Location of first HIV diagnosis
Study clinic 201 (68.1)
VCT centre 94 (31.9)
Has confirmed record of diagnosis
Yes, from study clinic 240 (81.4)
Yes, from VCT centre 19 (6.4)
No (self report only) 36 (12.2)
Year of first diagnosis
<2004 14 (4.7)
2004 188 (63.7)
2005 40 (13.6)
2006 53 (18.0)
Screened for ART eligibility within 2 years of diagnosis
No 47 (15.9)
Yes 248 (84.1)
CD4 count category at first ART screening
<=250 143 (57.7)
251–600 67 (27.0)
>=601 38 (15.3)
ART, antiretroviral therapy; VCT, voluntary counselling and
testing.
*Interval 1 is from November 2004 to October 2006 inclusive (the
2004 ⁄ 5 and 2005 ⁄ 6 HIV surveys).
Among the 248 individuals screened.
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aged 35–44 years. However, among those aged 45 years
and above, coverage was 63%. Coverage also varied with
marital status, with the highest coverage in widowed
persons (91%) and the lowest among the currently married
(58%).
Discussion
Based on 2003 Uganda national treatment guidelines
(Uganda Ministry of Health 2003), estimated overall ART
coverage in our rural programme was 69%, reflecting a
high level of ART access and uptake, once people were
diagnosed with HIV infection, but a low level of HIV
diagnosis. Diagnosis of HIV infection was the main
bottleneck in the successive steps that determine overall
ART coverage: diagnosis of HIV infection, screening for
ART eligibility and receiving ART. Our cross-sectional
analysis of HIV-positive participants who were still resident
in 2008 shows that slightly over half (56%) had been
diagnosed (i.e. knew their HIV status). However, among
those who were diagnosed, most (79%) had been screened
for ART eligibility. Our prospective analysis of HIV-
positive participants who were resident in 2004–2006
showed a similar picture – less than half had been diagnosed
by end 2006, but among those who were diagnosed, 84%
had been screened within 2 years of diagnosis.
The estimated 69% ART coverage in our programme is
higher than the estimated 53% coverage for Uganda
nationally in 2009 (WHO ⁄UNAIDS ⁄UNICEF, 2010) using
the previous WHO guidelines that recommended ART
initiation at CD4 count £200 cells ⁄mm3 (WHO 2006).
The results from our research programme with a long
presence in the local community and an intensive screening
approach represent ‘best practice’, and are therefore
unlikely to be representative of those obtained nationally
through routine service provision. A comparative analysis
of ART access in four population-based HIV cohort studies
in Africa found that coverage was higher in Masaka than in
sites in Malawi, Tanzania and Zimbabwe (Wringe et al.
2012). A study in Malawi showed that those accessing care
are those with the most advanced disease and the highest
mortality in absence of treatment (Jahn et al. 2008). In our
cohort, most people who were diagnosed with HIV
attended the study clinic, and so were screened for ART
Table 2 Factors associated with being
screened for ART initiation within 2 years,
among HIV-infected adults who were resi-
dent in the study area in Interval 1* and
knew their HIV status by end of 2006
n screened ⁄ total
HIV-positive
& diagnosed (%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
Gender P = 0.66 P = 0.78
Men 97 ⁄ 117 (82.9) 1 1
Women 151 ⁄ 178 (84.8) 1.15 [0.61, 2.17] 1.10 [0.56, 2.17]
Age (years) at diagnosis P = 0.70 P = 0.65
<25 23 ⁄ 30 (76.7) 1 1
25–34 88 ⁄ 105 (83.8) 1.58 [0.58, 4.25] 1.86 [0.65, 5.33]
35–44 91 ⁄ 106 (85.8) 1.85 [0.67, 5.05] 1.97 [0.66, 5.85]
45+ 46 ⁄ 54 (85.2) 1.75 [0.56, 5.42] 2.06 [0.62, 6.88]
Marital status at diagnosis P = 0.09 P = 0.08
Never married 13 ⁄ 14 (92.9) 3.37 [0.42, 26.9] 4.97 [0.57, 43.5]
Married 108 ⁄ 136 (79.4) 1 1
Divorced ⁄ separated 64 ⁄ 77 (83.1) 1.28 [0.62, 2.64] 1.23 [0.59, 2.56]
Widowed 57 ⁄ 62 (91.9) 2.96 [1.08, 8.07] 2.72 [0.98, 7.58]
Education at diagnosis P = 0.49 P = 0.43
None 27 ⁄ 34 (79.4) 0.48 [0.15, 1.58] 0.44 [0.13, 1.50]
Primary 1–4 52 ⁄ 61 (85.3) 0.72 [0.24, 2.18] 0.69 [0.22, 2.11]
Primary 5–7 92 ⁄ 114 (80.7) 0.67 [0.20, 1.38] 0.49 [0.18, 1.32]
Secondary or higher 48 ⁄ 54 (88.9) 1 1
Tribe P = 0.66 P = 0.79
Baganda 159 ⁄ 191 (83.2) 1 1
non-Baganda 81 ⁄ 95 (85.3) 1.16 [0.59, 2.30] 1.10 [0.54, 2.24]
ART, antiretroviral therapy; CI, confidence intervals; OR, odd ratios.
*Interval 1 is from November 2004 to October 2006 inclusive (the 2004 ⁄ 5 and 2005 ⁄ 6
HIV surveys).
Adjusted for age and marital status.
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eligibility at the time of diagnosis. However, in the general
population, both HIV diagnosis and access to ART
screening may be important bottlenecks in the coverage of
HIV services. Further pressure on ART coverage will come
with changes in policy, recommending that people living
with HIV should start on ART with a CD4 count of 350 or
500 cells ⁄mm3. Using a CD4 count of 350 as the threshold
for treatment, an estimated 73% of HIV-positive individ-
uals in our cohort in 2008 would be in need of ART, and
coverage would be only 45%.
In designing interventions to improve ART coverage, it is
important to know about the demographic factors affecting
ART access and uptake, but there have been few studies.
We have identified various factors associated with uptake of
ART screening after diagnosis that could be targeted in
developing strategies to improve HIV care programmes.
After adjusting for age, we found that among people who
had learned their HIV-positive status, married people were
less likely to be screened for ART within 2 years than those
who were never married, or who had been separated,
divorced or widowed. Studies have demonstrated spousal
barriers in the uptake of HIV services (De Paoli et al. 2004;
Muula & Kataika 2008). Neither disclosure nor domestic
violence was examined, but these concerns could contribute
to the lower uptake of ART and screening services among
married couples. The relatively low uptake of ART services
among young people and married people indicates the
scope for efforts to provide services that meet the needs of
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Figure 1 (a) HIV services coverage at end
of 2008, among 575 HIV-infected adults
who were alive and still resident in the
study area in Interval 21, by gender. (b) HIV
services coverage at end of 2008, among
575 HIV-infected adults who were alive
and still resident in the study area in
Interval 21, by age group. 1Interval 1 is
from November 2007 to October 2008
inclusive (the 2007 ⁄ 8 HIV survey).
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these groups. The need for ART is high among people with
HIV who are married, in whom HIV prevalence is high
(Government of Uganda 2010).
The main strength of our study is the ability to link
population-level HIV data with information from the only
ART provider in the study area, enabling us to assess the
proportion of HIV-infected persons who have been diag-
nosed, screened and started on ART. Information on age-
specific mortality and HIV incidence also enables us to
estimate ART need among the HIV-infected population,
providing a denominator, against which ART coverage can
be calculated, disaggregated by socio-demographic vari-
ables of interest.
A limitation is that, unlike data collection in the clinical
cohort study, data in the VCT centres are not routinely
collected for analysis purposes, and so, the VCT data may
be incomplete. Hence, we may have underestimated the
proportion of participants who know their HIV status. An
additional limitation is that our estimate of current access
to HIV services is based on HIV-positive adults who were
still alive during 2007 ⁄8, the most recent survey for which
complete data on services was available. Thus, we will
have missed people who died or moved away before the
2007 ⁄8 survey, and may be overestimating the proportion
of adults in the study area who access HIV services.
The roll-out of free ART in Uganda started in 2004 and
achieved an estimated 39% national coverage by 2009
(WHO ⁄UNAIDS ⁄UNICEF 2010) based on 2010 WHO
guidelines that recommend ART initiation at a CD4 count
of 350 cells ⁄mm3 (World Health Organization 2010). The
standard definition of ART coverage depends on set criteria
for unmet need (Mahy et al. 2010), enabling comparison of
coverage estimates that use the same eligibility criteria.
However, the change in the WHO recommended CD4
count threshold for ART initiation from 200 to
350 cells ⁄mm3 results in changes in coverage estimates,
which may decrease even as countries enrol greater
numbers of patients onto ART. Measures to complement
the existing UNGASS definition of ART coverage may be
useful, e.g. the enrolment ratio, in which the numerator is
the number of individuals starting ART in a given year, and
the denominator is the number of individuals becoming
eligible for ART in the same year, according to the ART
guidelines that are in place during that year (Johnson &
Boulle 2011). This ratio of ART initiation to HIV
progression provides a better reflection of recent pro-
gramme performance and a robust measure that is less
sensitive to changes in ART eligibility criteria.
Conclusions
Overall, ART coverage after 4 years of this rural programme
was 69%, reflecting high ART access and uptake once people
are diagnosed with HIV infection, but a low level of HIV
diagnosis. At least half of HIV-infected participants may not
know their status, even though in this setting, people have
more opportunities to learn their status than in other rural
areas in Uganda. However, once diagnosed, nearly all
participants who were eligible for ART were started on
treatment, owing to the intensive screening procedures in the
study clinic. This very high uptake of ART is unlikely to
reflect coverage in the general population. Intensified efforts
are needed to promote HIV testing and ART screening and
uptake among those found to be HIV-positive.
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Married 288 80 138 58
Divorced
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Secondary
or higher
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Tribe
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